Conexeu Sciences (NASDAQ:CNXU) Coverage Initiated by Analysts at HC Wainwright

Investment analysts at HC Wainwright began coverage on shares of Conexeu Sciences (NASDAQ:CNXU) in a report issued on Monday, MarketBeat Ratings reports. The brokerage set a “buy” rating and a $20.00 price target on the stock. HC Wainwright’s target price would suggest a potential upside of 50.60% from the company’s previous close.

Separately, Wall Street Zen upgraded Conexeu Sciences to a “hold” rating in a report on Saturday, May 30th. One research analyst has rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $20.00.

Conexeu Sciences Stock Performance

Shares of NASDAQ:CNXU opened at $13.28 on Monday. Conexeu Sciences has a twelve month low of $9.60 and a twelve month high of $18.79.

About Conexeu Sciences

Conexeu is a company focused on building a new class of collagen-based regenerative tissue products. The Company was incorporated on November 2, 2022 under the Business Corporations Act (British Columbia) and was continued out of British Columbia and domesticated into the State of Nevada under the laws of the State of Nevada on April 10, 2025. — Conexeu is an early-stage medical device company formed to acquire and commercialize intellectual property (“IP”) developed over more than a decade at the University of British Columbia (the “University”) and the BC Professional Firefighters Burn and Wound Healing Laboratory.